EGFR and lung carcinoma: In addition, some studies found that the aberrant expression and activation of MET result in the activation of the ERBB3/PI3K/AKT pathway, which is associated with the resistance of EGFR inhibitors in lung cancer, and this resistance can be reversed by combining MET inhibitors and EGFR inhibitors.